Summary
Objective
Methods
Results
Conclusions
Keywords
1. Introduction
World Health Organization. Global tuberculosis control 2011. Geneva: WHO; 2010. Available at: http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf (accessed July 3, 2012).
World Health Organization. Global tuberculosis control 2011. Geneva: WHO; 2010. Available at: http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf (accessed July 3, 2012).
World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: WHO; 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf (accessed April 20, 2011).
2. Materials and methods
2.1 Study data
Centers for Disease Control. Taiwan tuberculosis control report 2007, 2008, 2009, 2010. Taiwan: Centers for Disease Control, Department of Health. Available at: http://www.cdc.gov.tw (accessed August 13, 2010).
2.2 Resistant TB transmission model

Equation a Symbols: π=Nδ is the recruitment rate (per person-year) where δ is the birth rate (per year) and N is the total population size; p is the probability of new infections that develop progressive primary active TB within 1 year; ν is the progression rate from latency to active TB (per year); μ is the background mortality rate (per year); μS is the DS TB caused mortality rate (per year); μR is the MDR TB caused mortality rate (per year); σ is the factor reducing the risk of infection as a result of acquired immunity to a previous infection with sensitive and resistant TB; cs is the cure rate of active DS TB (per year); cR is the cure rate of active MDR TB (per year); cF is the proportion of DS TB treatment failure acquiring resistance; ECR is the effective contact rate (per year); βS is the transmission rate for DS TB (per person per year); βR is the transmission rate for MDR TB (per person per year). | Meaning | |
---|---|---|
Two-strain TB model | ||
(T1) | Susceptible individuals | |
(T2) | Latently infected individuals with DS TB | |
(T3) | Latently infected individuals with MDR TB | |
(T4) | DS infectious TB | |
(T5) | MDR infectious TB | |
Basic reproduction number | ||
(T6) | Basic reproduction number of DS TB | |
(T7) | Basic reproduction number of MDR TB |
2.3 Probabilistic DS/MDR TB risk model
2.4 Model parameterization and validation
Department of Statistics. Statistical yearbook of interior: population by age. Taiwan: Department of Statistics, Ministry of the Interior. Available at: http://www.moi.gov.tw/stat/index.aspx (accessed January 14, 2010).
2.5 Sensitivity and uncertainty analyses

3. Results
3.1 Population dynamics of DS/MDR TB
Sites | 2006 | 2007 | 2008 | 2009 | 2010 | Average |
---|---|---|---|---|---|---|
Hwalien County | 8.66 | 4.63 | 2.14 | 4.99 | 4.12 | 4.91 ± 2.37 |
Taitung County | 5.85 | 2.94 | 1.87 | 1.29 | 2.16 | 2.82 ± 1.79 |
Pingtung County | 1.33 | 1.26 | 0.99 | 0.57 | 0.68 | 0.97 ± 0.34 |
Taipei City | 0.62 | 0.36 | 0.46 | 0.38 | 0.35 | 0.43 ± 0.11 |
Centers for Disease Control. Taiwan tuberculosis control report 2007, 2008, 2009, 2010. Taiwan: Centers for Disease Control, Department of Health. Available at: http://www.cdc.gov.tw (accessed August 13, 2010).
Probability distribution | ||||
---|---|---|---|---|
Hwalien County | Taitung County | Pingtung County | Taipei City | |
Model parameter | ||||
p | N (0.08, 0.03) | |||
ν (per year) | N (0.00392, 0.0007) | |||
μ (per year) | LN (0.031, 2.05) | LN (0.031, 2.05) | LN (0.030, 2.11) | LN (0.027, 2.00) |
μS (per year) | N (0.037, 0.015) | N (0.040, 0.019) | N (0.052, 0.021) | N (0.033, 0.013) |
μR (per year) | N (0.30, 0.05) | |||
cS (per year) | N (0.64, 0.07) | N (0.61, 0.08) | N (0.68, 0.09) | N (0.72, 0.01) |
cR (per year) | LN (0.10, 2.68) | LN (0.08, 2.83) | LN (0.18, 1.89) | LN (0.28, 1.41) |
cF | N (0.034, 0.018) | N (0.024, 0.022) | N (0.017, 0.007) | N (0.016, 0.005) |
ECR (per year) | LN (7.40, 1.33) | |||
N (person) | N (345 297, 2748) | N (236 156, 3174) | N (893 289, 5625) | N (2 625 962, 8435) |
π (per person year) | 2960 | 2228 | 7284 | 21217 |
RF | N (0.32, 0.14) | |||
σ | 0.25 | |||
βS (per person per year) | LN (2.14 × 10−5, 1.33) | LN (3.13 × 10−5, 1.33) | LN (8.28 × 10−6, 1.33) | LN (2.82 × 10−6, 1.33) |
βR (per person per year) | LN (6.11 × 10−6, 1.91) | LN (8.93 × 10−6, 1.91) | LN (2.36 × 10−6, 1.91) | LN (8.03 × 10−7, 1.91) |
Initial population size k The initial population sizes in 2006 of N, TS, and TR are adopted from the Taiwan Tuberculosis Control Report.18 S=N − LS − LR − TS − TR. LS=0.004×0.92×0.99×N, and LR=0.004×0.92×0.01×N, where 0.004 is adopted from Yeh et al.,28 0.92=(1 − 0.08),24 and the proportions of infections that develop LS (0.99) and LR (0.01) are assumed. | ||||
N | 346 301 | 237 450 | 893 529 | 2 624 309 |
S | 344 338 | 236 153 | 888 554 | 2 612 793 |
LS | 1262 | 865 | 3241 | 9561 |
LR | 13 | 9 | 33 | 97 |
TS | 659 | 409 | 1690 | 1843 |
TR | 30 | 14 | 12 | 16 |
Department of Statistics. Statistical yearbook of interior: population by age. Taiwan: Department of Statistics, Ministry of the Interior. Available at: http://www.moi.gov.tw/stat/index.aspx (accessed January 14, 2010).
Centers for Disease Control. Taiwan tuberculosis control report 2007, 2008, 2009, 2010. Taiwan: Centers for Disease Control, Department of Health. Available at: http://www.cdc.gov.tw (accessed August 13, 2010).


3.2 DS/MDR TB infection risk estimates


3.3 Sensitivity analysis
Input parameter | Contribution (%) | |||
---|---|---|---|---|
Hwalien County | Taitung County | Pingtung County | Taipei City | |
RF | 41.20% | 40.51% | 41.81% | 44.35% |
p | 30.67% | 31.98% | 30.63% | 32.70% |
βS | 14.59% | 14.07% | 51.68% | 15.45% |
ν | 0.00% | 0.02% | 0.02% | 0.02% |
N | 0.00% | 0.01% | 0.00% | 0.00% |
μ | −1.18% | −0.80% | −1.34% | −1.34% |
μR | −3.19% | −2.32% | −2.05% | −1.58% |
cR | −9.16% | −10.29% | −8.47% | −4.57% |
4. Discussion
4.1 Population dynamics of DR TB
4.2 Infection risk estimates of DS/MDR TB
4.3 Limitations and implications
World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. Geneva: WHO; 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241501330_eng.pdf (accessed April 2, 2012).
References
World Health Organization. Global tuberculosis control 2011. Geneva: WHO; 2010. Available at: http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf (accessed July 3, 2012).
- The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis.Proc Natl Acad Sci U S A. 2009; 106: 14711-14715
- Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.Proc Natl Acad Sci U S A. 2009; 106: 13980-13985
- Tuberculosis: what we don’t know can, and does, hurt us.Science. 2010; 328: 852-856
World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: WHO; 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf (accessed April 20, 2011).
- Erasing the world's slow strain: strategies to beat multidrug-resistant tuberculosis.Science. 2002; 295: 2042-2046
- Treatment of multidrug-resistant tuberculosis.N Engl J Med. 1993; 329: 784-791
- Worldwide emergence of extensively drug-resistant tuberculosis.Emerg Infect Dis. 2007; 13: 380-387
Centers for Disease Control. National notifiable disease surveillance system. Taiwan: Centers for Disease Control, Department of Health. Available at: /(accessed August 19, 2011).
- Control strategies for tuberculosis epidemics: new models for old problems.Science. 1996; 273: 497-500
- Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework.J Mol Med. 1998; 76: 624-636
- Criteria for the control of drug-resistant tuberculosis.Proc Natl Acad Sci U S A. 2000; 97: 8180-8185
- Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness.Nat Med. 2004; 10: 1117-1121
- Drug resistance in tuberculosis—a reinfection model.Theor Popul Biol. 2007; 71: 196-212
- Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing.Proc Natl Acad Sci U S A. 2008; 105: 11293-11298
- The effect of drug resistance on the fitness of Mycobacterium tuberculosis.Lancet Infect Dis. 2003; 3: 13-21
- Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis.Int J Tuberc Lung Dis. 2009; 13: 1456-1466
Centers for Disease Control. Taiwan tuberculosis control report 2007, 2008, 2009, 2010. Taiwan: Centers for Disease Control, Department of Health. Available at: http://www.cdc.gov.tw (accessed August 13, 2010).
- Clinical consequences and transmissibility of drug-resistant tuberculosis in Southern Mexico.Arch Intern Med. 2000; 160: 630-636
- Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission.Math Biosci. 2002; 180: 29-48
- Infectious diseases of humans: dynamics and control.Oxford University Press, Oxford1991
- Planning for smallpox outbreaks.Nature. 2003; 425: 681-685
Department of Statistics. Statistical yearbook of interior: population by age. Taiwan: Department of Statistics, Ministry of the Interior. Available at: http://www.moi.gov.tw/stat/index.aspx (accessed January 14, 2010).
- Prospects for worldwide tuberculosis control under the WHO DOTS strategy.Lancet. 1998; 352: 1886-1891
- The intrinsic transmission dynamics of tuberculosis epidemics.Nat Med. 1995; 1: 815-821
- Will tuberculosis become resistant to all antibiotics?.Proc Biol Sci. 2001; 268: 45-52
- Quantifying the intrinsic transmission dynamics of tuberculosis.Theor Popul Biol. 1998; 54: 117-132
- Tuberculin reactivity in adults after 50 years of universal bacille Calmette–Guérin vaccination in Taiwan.Trans R Soc Trop Med Hyg. 2005; 99: 509-516
- Modeling the emergence of the ‘hot zones’: tuberculosis and the amplification dynamics of drug resistance.Nat Med. 2004; 10: 1111-1116
- Mycobacterium tuberculosis in Taiwan.J Infect. 2006; 52: 77-85
- Challenges and solutions in improving tuberculosis care among aboriginal people in Taiwan.East-West Center Working Papers. 2006; 32: 1-7
- Molecular epidemiology of multidrug-resistant Mycobacterium tuberculosis in Eastern Taiwan.Int J Tuberc Lung Dis. 2010; 14: 924-926
- Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis.PLoS Med. 2011; 8: e1001074
- The challenge of new drug discovery for tuberculosis.Science. 2011; 469: 483-490
- Reducing the global burden of tuberculosis: the contribution of improved diagnostics.Nature. 2006; 444: 49-57
- Association between smoking and tuberculosis infection: a population survey in a high tuberculosis incidence area.Thorax. 2005; 60: 555-557
World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. Geneva: WHO; 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241501330_eng.pdf (accessed April 2, 2012).
- Drug resistance pattern of Mycobacterium tuberculosis complex at a medical center in central Taiwan, 2003–2007.J Microbiol Immunol Infect. 2010; 43: 285-290
- Effect of drug resistance on the generation of secondary cases of tuberculosis.J Infect Dis. 2003; 188: 1878-1884
- Epidemiology of tuberculosis.Royal Netherlands Tuberculosis Association, Hague1991
- Interpreting the decline in tuberculosis: the role of secular trends in effective contact.Int J Epidemiol. 1999; 28: 327-334
- Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness.Lancet. 2006; 367: 1173-1180
Article info
Publication history
Identification
Copyright
User license
Elsevier user license |
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy